<DOC>
	<DOCNO>NCT01671683</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety additional neoadjuvant chemotherapy capecitabine rest period patient locally advanced rectal cancer .</brief_summary>
	<brief_title>Additional Chemotherapy After Neoadjuvant Chemoradiotherapy Patients With Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>Neoadjuvant chemoradiotherapy ( NCRT ) use standard treatment modality patient locally advanced rectal cancer ( LARC ) increase local control , enhance sphincter preservation , less toxicity.NCRT enhance down-staging tumor reduce local recurrence . However , survival benefit NCRT demonstrate rate distant metastasis still report high 30 % . Patients pathologic complete remission ( pCR ) NCRT show excellent survival benefit . We infer additional chemotherapy resting period could enhance pCR rate . The aim present study evaluate safety efficacy additional 4-week chemotherapy capecitabine conventional 6-week NCRT patient LARC .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>histologically proven , locally advanced adenocarcinoma rectum Eastern Cooperative Oncology Group ( ECOG ) score 02 adequate function major organ sign informed consent . coexist malignancy malignancy within last 5 year prior enrollment severe concurrent medical psychiatric disorder prior RT pelvis pregnant lactating patient</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>neoadjuvant chemoradiotherapy</keyword>
	<keyword>Capecitabine</keyword>
</DOC>